INOVIO PHARMACEUTICALS INC (INO) Fundamental Analysis & Valuation

NASDAQ:INO • US45773H4092

Current stock price

1.5741 USD
-0.01 (-0.37%)
Last:

This INO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. INO Profitability Analysis

1.1 Basic Checks

  • INO had negative earnings in the past year.
  • INO had a negative operating cash flow in the past year.
  • INO had negative earnings in each of the past 5 years.
  • INO had a negative operating cash flow in each of the past 5 years.
INO Yearly Net Income VS EBIT VS OCF VS FCFINO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -100M -200M -300M

1.2 Ratios

  • With a Return On Assets value of -114.31%, INO is not doing good in the industry: 79.38% of the companies in the same industry are doing better.
  • INO has a Return On Equity of -352.53%. This is in the lower half of the industry: INO underperforms 73.99% of its industry peers.
Industry RankSector Rank
ROA -114.31%
ROE -352.53%
ROIC N/A
ROA(3y)-96.03%
ROA(5y)-85.92%
ROE(3y)-208.08%
ROE(5y)-165.21%
ROIC(3y)N/A
ROIC(5y)N/A
INO Yearly ROA, ROE, ROICINO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -1K -2K -3K

1.3 Margins

  • INO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
INO Yearly Profit, Operating, Gross MarginsINO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20K -40K -60K -80K -100K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. INO Health Analysis

2.1 Basic Checks

  • INO does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for INO has been increased compared to 1 year ago.
  • The number of shares outstanding for INO has been increased compared to 5 years ago.
  • There is no outstanding debt for INO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
INO Yearly Shares OutstandingINO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
INO Yearly Total Debt VS Total AssetsINO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

2.2 Solvency

  • INO has an Altman-Z score of -36.47. This is a bad value and indicates that INO is not financially healthy and even has some risk of bankruptcy.
  • INO's Altman-Z score of -36.47 is on the low side compared to the rest of the industry. INO is outperformed by 89.98% of its industry peers.
  • INO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -36.47
ROIC/WACCN/A
WACC9.28%
INO Yearly LT Debt VS Equity VS FCFINO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M

2.3 Liquidity

  • INO has a Current Ratio of 1.40. This is a normal value and indicates that INO is financially healthy and should not expect problems in meeting its short term obligations.
  • INO's Current ratio of 1.40 is on the low side compared to the rest of the industry. INO is outperformed by 83.04% of its industry peers.
  • INO has a Quick Ratio of 1.40. This is a normal value and indicates that INO is financially healthy and should not expect problems in meeting its short term obligations.
  • INO's Quick ratio of 1.40 is on the low side compared to the rest of the industry. INO is outperformed by 82.08% of its industry peers.
Industry RankSector Rank
Current Ratio 1.4
Quick Ratio 1.4
INO Yearly Current Assets VS Current LiabilitesINO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. INO Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 54.14% over the past year.
  • Looking at the last year, INO shows a very negative growth in Revenue. The Revenue has decreased by -70.02% in the last year.
  • The Revenue for INO have been decreasing by -61.18% on average. This is quite bad
EPS 1Y (TTM)54.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%110%
Revenue 1Y (TTM)-70.02%
Revenue growth 3Y-81.47%
Revenue growth 5Y-61.18%
Sales Q2Q%-100%

3.2 Future

  • The Earnings Per Share is expected to grow by 21.53% on average over the next years. This is a very strong growth
  • INO is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 397.50% yearly.
EPS Next Y20.26%
EPS Next 2Y37.76%
EPS Next 3Y29.87%
EPS Next 5Y21.53%
Revenue Next Year16948.9%
Revenue Next 2Y2612%
Revenue Next 3Y1134.23%
Revenue Next 5Y397.51%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
INO Yearly Revenue VS EstimatesINO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 50M 100M 150M 200M 250M
INO Yearly EPS VS EstimatesINO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 -5 -10 -15

More info and screens

Find the best growth stocksShow best growing peers

1

4. INO Valuation Analysis

4.1 Price/Earnings Ratio

  • INO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for INO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
INO Price Earnings VS Forward Price EarningsINO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
INO Per share dataINO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

  • A more expensive valuation may be justified as INO's earnings are expected to grow with 29.87% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y37.76%
EPS Next 3Y29.87%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. INO Dividend Analysis

5.1 Amount

  • INO does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

INO Fundamentals: All Metrics, Ratios and Statistics

INOVIO PHARMACEUTICALS INC

NASDAQ:INO (3/23/2026, 10:10:56 AM)

1.5741

-0.01 (-0.37%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-12
Earnings (Next)05-11
Inst Owners48.07%
Inst Owner Change61.51%
Ins Owners0.48%
Ins Owner Change2.22%
Market Cap108.75M
Revenue(TTM)65.30K
Net Income(TTM)-84.95M
Analysts80
Price Target8.36 (431.1%)
Short Float %16.03%
Short Ratio9.4
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)6.52%
Min EPS beat(2)-103.56%
Max EPS beat(2)116.6%
EPS beat(4)3
Avg EPS beat(4)14.72%
Min EPS beat(4)-103.56%
Max EPS beat(4)116.6%
EPS beat(8)5
Avg EPS beat(8)9.39%
EPS beat(12)7
Avg EPS beat(12)7.33%
EPS beat(16)8
Avg EPS beat(16)4%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-4.21%
PT rev (3m)7.42%
EPS NQ rev (1m)2.7%
EPS NQ rev (3m)2.7%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.98%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)-24.98%
Revenue NY rev (3m)-11.2%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1665.46
P/FCF N/A
P/OCF N/A
P/B 4.51
P/tB 4.51
EV/EBITDA N/A
EPS(TTM)-1.83
EYN/A
EPS(NY)-1.46
Fwd EYN/A
FCF(TTM)-1.29
FCFYN/A
OCF(TTM)-1.28
OCFYN/A
SpS0
BVpS0.35
TBVpS0.35
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -114.31%
ROE -352.53%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-96.03%
ROA(5y)-85.92%
ROE(3y)-208.08%
ROE(5y)-165.21%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 20.15%
Cap/Sales 437.52%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.4
Quick Ratio 1.4
Altman-Z -36.47
F-Score1
WACC9.28%
ROIC/WACCN/A
Cap/Depr(3y)19.86%
Cap/Depr(5y)23.5%
Cap/Sales(3y)233.35%
Cap/Sales(5y)155.77%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)54.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%110%
EPS Next Y20.26%
EPS Next 2Y37.76%
EPS Next 3Y29.87%
EPS Next 5Y21.53%
Revenue 1Y (TTM)-70.02%
Revenue growth 3Y-81.47%
Revenue growth 5Y-61.18%
Sales Q2Q%-100%
Revenue Next Year16948.9%
Revenue Next 2Y2612%
Revenue Next 3Y1134.23%
Revenue Next 5Y397.51%
EBIT growth 1Y22.38%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y14.97%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y14.84%
OCF growth 3YN/A
OCF growth 5YN/A

INOVIO PHARMACEUTICALS INC / INO Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for INOVIO PHARMACEUTICALS INC?

ChartMill assigns a fundamental rating of 2 / 10 to INO.


What is the valuation status of INOVIO PHARMACEUTICALS INC (INO) stock?

ChartMill assigns a valuation rating of 1 / 10 to INOVIO PHARMACEUTICALS INC (INO). This can be considered as Overvalued.


Can you provide the profitability details for INOVIO PHARMACEUTICALS INC?

INOVIO PHARMACEUTICALS INC (INO) has a profitability rating of 0 / 10.


Can you provide the financial health for INO stock?

The financial health rating of INOVIO PHARMACEUTICALS INC (INO) is 5 / 10.


What is the expected EPS growth for INOVIO PHARMACEUTICALS INC (INO) stock?

The Earnings per Share (EPS) of INOVIO PHARMACEUTICALS INC (INO) is expected to grow by 20.26% in the next year.